Statement of Principles concerning Graves disease (Reasonable Hypothesis) (No. 7 of 2022) (Cth)

Statement of Principles concerning GRAVES DISEASE (Reasonable Hypothesis) (No. 7 of 2022) The Repatriation Medical Authority determines the following Statement of Principles under subsection 196B(2) of the Veterans' Entitlements Act 1986.

Dated 24 December 2021

The Common Seal of the Repatriation Medical Authority was affixed to this instrument at the direction of:

Professor Terence Campbell AM Chairperson

Contents 1 Name 2 Commencement 3 Authority 4 Repeal 5 Application 6 Definitions 7 Kind of injury, disease or death to which this Statement of Principles relates 8 Basis for determining the factors 9 Factors that must exist 10 Relationship to service 11 Factors referring to an injury or disease covered by another Statement of Principles Schedule 1 - Dictionary 1 Definitions

1 Name This is the Statement of Principles concerning Graves disease (Reasonable Hypothesis) (No. 7 of 2022). 2 Commencement This instrument commences on 31 January 2022. 3 Authority This instrument is made under subsection 196B(2) of the Veterans' Entitlements Act 1986. 4 Repeal The Statement of Principles concerning Graves' disease No. 33 of 2013 (Federal Register of Legislation No. F2013L00736) made under subsections 196B(2) and (8) of the VEA is repealed. 5 Application This instrument applies to a claim to which section 120A of the VEA or section 338 of the Military Rehabilitation and Compensation Act 2004 applies. 6 Definitions The terms defined in the Schedule 1 - Dictionary have the meaning given when used in this instrument. 7 Kind of injury, disease or death to which this Statement of Principles relates (1) This Statement of Principles is about Graves disease and death from Graves disease. Meaning of Graves disease (2) For the purposes of this Statement of Principles, Graves disease means a chronic autoimmune disease primarily affecting the thyroid gland, in which thyroid antibodies activate the thyroid-stimulating hormone receptor, causing thyroid hyperplasia and excessive thyroid hormone synthesis and secretion. Note 1: The thyroid-stimulating immunoglobulins can also affect the eyes, causing a characteristic ophthalmopathy (Graves orbitopathy), and less commonly the skin, causing a characteristic dermopathy (pretibial myxoedema). Note 2: Presenting features typically include a diffuse hyperplastic goitre and hyperthyroidism, although some patients may be euthyroid or hypothyroid during the course of the disease. Note 3: Graves disease may present as a thyrotoxic crisis. Note 4: thyrotoxic crisis is defined in the Schedule 1 - Dictionary. (3) While Graves disease attracts ICD‑10‑AM code E05.0 or E05.5, in applying this Statement of Principles the meaning of Graves disease is that given in subsection (2). (4) For subsection (3), a reference to an ICD-10-AM code is a reference to the code assigned to a particular kind of injury or disease in The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM), Tenth Edition, effective date of 1 July 2017, copyrighted by the Independent Hospital Pricing Authority, ISBN 978-1-76007-296-4. Death from Graves disease (5) For the purposes of this Statement of Principles, Graves disease, in relation to a person, includes death from a terminal event or condition that was contributed to by the person's Graves disease. Note: terminal event is defined in the Schedule 1 - Dictionary. 8 Basis for determining the factors The Repatriation Medical Authority is of the view that there is sound medical‑scientific evidence that indicates that Graves disease and death from Graves disease can be related to relevant service rendered by veterans, members of Peacekeeping Forces, or members of the Forces under the VEA, or members under the MRCA. Note: MRCA, relevant service and VEA are defined in the Schedule 1 - Dictionary. 9 Factors that must exist At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting Graves disease or death from Graves disease with the circumstances of a person's relevant service: (1) having iodine excess within the 6 months before the clinical onset of Graves disease; Note 1: Iodine excess may be due to consuming foods, dietary supplements or medications with a high content of iodine. Note 2: iodine excess is defined in the Schedule 1 - Dictionary. (2) taking a drug from the specified list of drugs within the 2 years before the clinical onset of Graves disease; Note: specified list of drugs is defined in the Schedule 1 - Dictionary. (3) being treated with alemtuzumab or antithymocyte globulin within the 10 years before the clinical onset of Graves disease; (4) taking amiodarone for a continuous period of at least 6 weeks, within the 2 years before the clinical onset of Graves disease; (5) undergoing a course of therapeutic radiation for cancer, where the thyroid gland was in the field of radiation, within the 25 years before the clinical onset of Graves disease; (6) having received iodine-131 (radioactive iodine) for the treatment of nodular goitre within the 10 years before the clinical onset of Graves disease; (7) having smoked tobacco products: (a) in an amount of at least 3 pack-years before the clinical onset of Graves disease; and (b) if smoking has ceased before the clinical onset of Graves disease, then that onset occurred within 10 years of cessation; Note: one pack-year is defined in the Schedule 1 - Dictionary. (8) being pregnant or within the 18 months postpartum at the time of the clinical onset of Graves disease; (9) having ethanol injection into the thyroid gland for the treatment of a thyroid adenoma within the 6 months before the clinical onset of Graves disease; (10) having trauma to the eye within the 6 months before the clinical onset of Graves disease; Note: Trauma to the eye may include blunt or penetrating physical injury to the eye. (11) for Graves disease first presenting as thyrotoxic crisis only, having an acute precipitating event within the 48 hours before the clinical onset of Graves disease; Note: acute precipitating event and thyrotoxic crisis are defined in the Schedule 1 - Dictionary. (12) having iodine excess within the 6 months before the clinical worsening of Graves disease; Note 1: Iodine excess may be due to consuming foods, dietary supplements or medications with a high content of iodine. Note 2: iodine excess is defined in the Schedule 1 - Dictionary. (13) taking a drug from the specified list of drugs within the 2 years before the clinical worsening of Graves disease; Note: specified list of drugs is defined in the Schedule 1 - Dictionary. (14) being treated with alemtuzumab or antithymocyte globulin within the 10 years before the clinical worsening of Graves disease; (15) taking amiodarone for a continuous period of at least 6 weeks, within the 2 years before the clinical worsening of Graves disease; (16) undergoing a course of therapeutic radiation for cancer, where the thyroid gland was in the field of radiation, within the 25 years before the clinical worsening of Graves disease; (17) having received iodine-131 (radioactive iodine) for the treatment of nodular goitre within the 10 years before the clinical worsening of Graves disease; (18) having smoked tobacco products: (a) in an amount of at least 3 pack-years before the clinical worsening of Graves disease; and (b) if smoking has ceased before the clinical worsening of Graves disease, then that worsening occurred within 10 years of cessation; Note: one pack-year is defined in the Schedule 1 - Dictionary. (19) being pregnant or within the 18 months postpartum at the time of the clinical worsening of Graves disease; (20) having ethanol injection into the thyroid gland for the treatment of a thyroid adenoma within the 6 months before the clinical worsening of Graves disease; (21) having trauma to the eye within the 6 months before the clinical worsening of Graves disease; Note: Trauma to the eye may include blunt or penetrating physical injury to the eye. (22) for thyrotoxic crisis only, having an acute precipitating event within the 48 hours before that clinical worsening of Graves disease; Note: acute precipitating event and thyrotoxic crisis are defined in the Schedule 1 – Dictionary. (23) inability to obtain appropriate clinical management for Graves disease. 10 Relationship to service (1) The existence in a person of any factor referred to in section 9, must be related to the relevant service rendered by the person. (2) The factors set out in subsections 9(12) to 9(23) apply only to material contribution to, or aggravation of, Graves disease where the person's Graves disease was suffered or contracted before or during (but did not arise out of) the person's relevant service. 11 Factors referring to an injury or disease covered by another Statement of Principles In this Statement of Principles: (1) if a factor referred to in section 9 applies in relation to a person; and (2) that factor refers to an injury or disease in respect of which a Statement of Principles has been determined under subsection 196B(2) of the VEA; then the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.